Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
Rhea-AI Summary
Relay Therapeutics (NASDAQ:RLAY), a clinical-stage precision medicine company focused on developing therapies for cancer and genetic diseases, has announced its participation in two major investor conferences in September 2025.
Management will engage in fireside chats at the 2025 Wells Fargo Healthcare Conference on September 4 at 2:15 p.m. ET and the Morgan Stanley 23rd Annual Global Conference on September 10 at 11:30 a.m. ET. Both presentations will be available via webcast on the company's investor relations website, with replays accessible for 30 days after the events.
Positive
- None.
Negative
- None.
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September:
- 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 at 2:15 p.m. ET
- Morgan Stanley 23rd Annual Global Conference on Wednesday, September 10, 2025 at 11:30 a.m. ET
The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay's Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, RLY-2608, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. RLY-2608 is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular malformations. Relay's pipeline also includes late-stage research programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com or follow us on LinkedIn.
Contact:
Pete Rahmer
prahmer@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
When is Relay Therapeutics (RLAY) presenting at the Wells Fargo Healthcare Conference 2025?
When is RLAY's presentation at the Morgan Stanley Global Conference 2025?
How can investors access Relay Therapeutics' (RLAY) conference presentations?
What type of company is Relay Therapeutics (RLAY)?
